Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

Tiziana Life Sciences announced initiation of a Phase Ib clinical trial to evaluate orally administered enteric-coated capsules of foralumab in patients with mild-to-moderate Crohn’s Disease.